Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy

By Davis Keith L.   Tangirala Muralikrishna   Meyers Juliana L.   Wei Wenhui  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1083-1091

Informa Healthcare

Access to resources Recommend Favorite

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

By Ray Joshua A.   Boye Kristina S.   Yurgin Nicole   Valentine William J.   Roze Stéphane   McKendrick Jan   Tucker Daniel M. D.   Foos Volker   Palmer Andrew J.  

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 609-622

Informa Healthcare

Access to resources Recommend Favorite

Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes

By Brodows Robert G.   Qu Yongming   Johns Don   Kim Dennis   Holcombe John H.  

Current Medical Research and Opinion, Vol. 24, Iss. 5, 2008-05 ,pp. : 1395-1397

Informa Healthcare

Access to resources Recommend Favorite

Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies

By Xie Lin   Wei Wenhui   Pan Chunshen   Baser Onur  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1137-1145

Informa Healthcare

Access to resources Recommend Favorite

A Real‐World Study of the Effect of Timing of Insulin Initiation on Outcomes in Older Medicare Beneficiaries with Type 2 Diabetes Mellitus

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 63, Iss. 5, 2015-05 ,pp. : 893-901

John Wiley & Sons Inc

Access to resources Recommend Favorite